SRR2779596
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.500
- MYC_TARGETS_V2+0.400
- OXIDATIVE_PHOSPHORYLATION+0.400
- PROTEIN_SECRETION+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- PI3K_AKT_MTOR_SIGNALING+0.300
- ANDROGEN_RESPONSE+0.200
- DNA_REPAIR+0.200
- MTORC1_SIGNALING+0.200
- ADIPOGENESIS+0.100
Top 10 suppressed
- ANGIOGENESIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- APICAL_SURFACE-0.400
- INFLAMMATORY_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- KRAS_SIGNALING_DN-0.400
- KRAS_SIGNALING_UP-0.400
- ALLOGRAFT_REJECTION-0.300
- COAGULATION-0.300
- ESTROGEN_RESPONSE_EARLY-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s0112303 | — | — | 0.842 |
| 2 | BS_K74PZET7 | Med | Medulloblastoma | 0.838 |
| 3 | SJEPD003_D.RNA-Seq | EPN | Supratentorial EPN | 0.829 |
| 4 | BS_JFB984RG | Med | Medulloblastoma | 0.823 |
| 5 | SRR26320097 | — | — | 0.823 |
| 6 | R224 | — | — | 0.818 |
| 7 | SRR12202452 | — | — | 0.816 |
| 8 | 28541e4e-2e2b-4772-9566-acf35b31a581 | — | — | 0.816 |
| 9 | MDT-AP-3088 | Med | Medulloblastoma | 0.816 |
| 10 | MDT-AP-1353 | Med | Medulloblastoma | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |